Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | SGN-PDL1V |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | SGN-PDL1V | Phase I | Actionable | In a Phase I trial, SGN-PDL1V treatment demonstrated manageable safety and resulted in an objective response rate of 27.3% and a median duration of response of 7.9 months in patients with CD274-positive advanced solid tumors (n=55), including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and esophageal cancer (Ann Oncol (2024) 35 (suppl_2): S486;NCT05208762). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| 607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors | Full reference... |